Current Rheumatology Reports

, 15:358

First online:

Top 10 Developments in Lupus Nephritis

  • Teresa K. ChenAffiliated withDivision of Nephrology, The Johns Hopkins University School of Medicine Email author 
  • , Derek M. FineAffiliated withDivision of Nephrology, The Johns Hopkins University School of Medicine

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Lupus nephritis affects up to 60 % of patients with systemic lupus erythematosus and is associated with worse clinical outcomes. Traditionally, it has been treated with high-dose immunosuppression consisting of cyclophosphamide and prednisone; however, recent trials have demonstrated mycophenolate mofetil as a safe and effective alternative for both induction and maintenance of disease. Other progress has been made in our understanding of the pathogenesis of lupus nephritis, outcomes in renal transplantation, and associations with genetic risk factors. This review highlights key developments in our understanding of lupus nephritis over the past decade.


Lupus nephritis Kidney Proliferative lupus nephritis Membranous lupus nephritis Renal transplantation APOL1 Induction therapy Maintenance therapy Systemic lupus erythematosus SLE Mycophenolate mofetil Rituximab Treatment Multitargeted therapy Epidemiology